Username
Password
Forget Password?
  1. Indices
  2. Commodities
  3. Currencies
Straits Times 3,134.71 +18.54 +0.59%
Hang Seng 26,664.28 +160.35 +0.61%
Dow Jones 27,024.80 +237.44 +0.89%
Shanghai Composite 2,978.71 -12.33 -0.41%
iX Biopharma Successfully Completes Pilot Bioavailability Study
Daily Bulletin | 26 November 2015
Related stocks:
42C
By:

iX Biopharma has successfully completed a pilot bioavailability study for PheoniX™, a product currently being developed for the treatment of male erectile dysfunction.

PheoniX™ is one of three products currently under development by the group. The product administers sildenafil via its proprietary sublingual drug delivery technology, Waferix™. The results of the pilot bioavailability study demonstrated that the sublingual wafer formulation of PheoniX™ has a similar rate and extent of drug absorption as a Viagra® tablet. The group intends to conduct a pivotal bioequivalence study for marketing authorisation, planned for the first quarter of 2016 as previously scheduled, to coincide with the upscaling of commercial production.

iX Biopharma  0.205 +0.006 +3.02%   
Business: Late-stage specialty pharmaceutical firm. [FY18 Turnover] Chemical analysis (95.6%), nutraceutical (2.4%), specialty pharmaceutical (2%).

Insight: May-19, 9M19 revenue jumped 206.2% due to project ... Read More


Join The Conversation
The Shares Investment editorial team welcomes constructive feedback on our coverage and content. We would also be delighted to answer any questions on the above article. Leave us a comment below, and we'll get back to you shortly!

All Rights Reserved. Pioneers & Leaders (Publishers) Pte Ltd. Best viewed with Mozilla Firefox 3.5 and above.